Highlights d Transcriptional expression of VDR is associated with differentiation prognosis in AML d VDR expression is partially regulated by methylation d Combined use of hypomethylating agents and VD analog targets leukemic stem cells SUMMARY Vitamin D (VD) is a known differentiating agent, but the role of VD receptor (VDR) is still incompletely described in acute myeloid leukemia (AML), whose treatment is based mostly on antimitotic chemotherapy. Here, we present an unexpected role of VDR in normal hematopoiesis and in leukemogenesis. Limited VDR expression is associated with impaired myeloid progenitor differentiation and is a new prognostic factor in AML. In mice, the lack of Vdr results in increased numbers of hematopoietic and leukemia stem cells and quiescent hematopoietic stem cells. In addition, malignant transformation of Vdr À/À cells results in myeloid differentiation block and increases self-renewal. Vdr promoter is methylated in AML as in CD34 + cells, and demethylating agents induce VDR expression. Association of VDR agonists with hypomethylating agents promotes leu-kemia stem cell exhaustion and decreases tumor burden in AML mouse models. Thus, Vdr functions as a regulator of stem cell homeostasis and leukemic propagation.
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INTRODUCTION
Acute myeloid leukemia (AML) is a heterogeneous disorder with a poor prognosis and is the most frequent form of acute leukemia in adults. Recently, it has been shown that disease heterogeneity is derived from differences in somatic mutations among individual patients (Patel et al., 2012) . Recurrent mutations in normal karyotype AML (which constitutes nearly 50% of cases) target a set of approximately 30 genes, most frequently FLT3, NPM1, KIT, CEBPA, and MLL (Ley et al., 2013; Patel et al., 2012; Welch et al., 2012) . These mutations affect self-renewal, cell survival and proliferation, and myeloid differentiation, impairing hematopoiesis and promoting accumulation of undifferentiated blasts (Ferrara and Schiffer, 2013; Lö wenberg et al., 1999; Mardis et al., 2009) . Vitamin D (VD), whose availability modulates hematopoietic stem and progenitor cell (HSPC) production (Cortes et al., 2016) , has potential antineoplastic properties (Campbell and Trump, 2017; Giovannucci et al., 2006) . VD promotes cell differentiation in numerous tissues, such as prostate, breast, and the hematopoietic system (Jacobs et al., 2016; Samuel and Sitrin, 2008) , through genomic activity that relies mostly on its association with VD receptor (VDR). In addition, VDR targets genes that are essential to cell cycle progression, another cancer feature (Campbell and Trump, 2017; Samuel and Sitrin, 2008) . Therefore, VDR is a promising target in cancer therapy. VDR belongs to the nuclear receptor family, such as the retinoic acid receptor (RAR), which is implicated in leukemogenesis in acute promyelocytic leukemia (APL), an AML subtype related to the t(15;17) translocation (Arber et al., 2016) . The use of suprapharmacologic dose of RAR agonist (RARa) in APL has permitted a major advance in AML therapy through the targeting of leukemia stem cells (LSCs) (Ablain et al., 2013 (Ablain et al., , 2014 . However, clinical trials with VD analogs in AML have been disappointing, mostly because of adverse effects such as life-threatening hypercalcemia (Cao et al., 2017; Kim et al., 2012) .
Despite chemotherapy and allogeneic stem cell transplantation regimens, AML management remains a challenge. Although many leukemic cells are typically sensitive to chemotherapy, relapses occur frequently and most of the time lead to death. Relapses result from the failure of available therapies to eradicate LSCs, which are able to self-renew, expand, and reestablish the disease (Bonnet and Dick, 1997; Passegué and Weisman, 2005; Terpstra et al., 1996) . Therefore, therapies aiming to target LSCs (while preserving hematopoietic stem cells [HSC] ) should help improve therapeutic efficacy and patient survival.
DNA methylation plays a critical role in AML pathogenesis, and different AML subtypes are characterized by distinct epigenetic signatures (Akalin et al., 2012; Figueroa et al., 2010) , thus providing insight into the potential for treatment options (Abdel-Wahab and Levine, 2013) . Moreover, in myelodysplastic syndromes (MDS), DNA methylation predicts response to demethylating agents (Shen et al., 2010) , and the use of DNA methyltransferase inhibitors (e.g., 5-azacytidine [5-aza] , decitabine [DAC] ) decreases rates of AML transformation (Fenaux et al., 2010) . However, response rates are short lived, and the molecular mechanisms underlying the efficacy of DNA methyltransferase inhibitors are not well understood (Garcia-Manero and Fenaux, 2011) .
We have previously shown that iron deprivation therapy promotes monocytic differentiation of AML cells (Callens et al., 2010a) . Analysis of gene expression patterns revealed that 30% of the most significant genes induced by therapy targeting iron homeostasis presented a VDR signaling signature. Iron chelating agents acted synergistically with 1,25-dihydroxyvitamin D3 through the induction of VDR signaling and activation of the downstream mitogen-activated protein kinase (MAPK) pathway. Moreover, we showed that combined therapy with iron chelators and VD was associated with increased overall survival (OS) in a retrospective cohort of elderly patients and that circulating VD levels predicted OS in AML (Paubelle et al., 2013) , an observation that was confirmed by others (Lee et al., 2014; Paubelle et al., 2013) . Therefore, induction of VDR expres-sion and activity represents a potential therapeutic target in AML, particularly in elderly patients non-eligible for intensive chemotherapy or allogeneic bone marrow transplantation (BMT) (Ferrara, 2014; Russell, 2012) .
Here, we investigated the correlation between VDR expression and activity and the molecular mechanisms involved in AML pathogenesis. We show that Vdr expression is downregulated by DNA methylation and that low expression of Vdr is involved in HSC and LSC homeostasis with important implications for AML prognosis and therapy.
RESULTS

Vdr Expression Is Associated with Monocyte
Differentiation and Patient Survival in AML VD is a compound well known to induce AML differentiation, but the role of VDR has never been investigated in leukemogenesis. To evaluate VDR expression and activity in AML, we analyzed a previously published gene expression dataset (GEO: GSE12417) (Metzeler et al., 2008) that includes normal karyotype AML patients (n = 163) classified according to the French-American-British (FAB) system (Bennett et al., 1976) . In this patient cohort, we found that Vdr expression was higher in AML subtypes with features of monocytic differentiation (AML4 and AML5) compared with immature or undifferentiated AML subtypes (AML0, AML1, and AML2). Not surprisingly, AML6 subtype exhibited a low level of Vdr expression ( Figure 1A ). Expression of monocyte differentiation markers such as CD14 and CSF1R (Friedman, 2002) did not differ between AML0-2 and AML4-5 subtypes (Figures S1A and S1B), suggesting that these markers do not correlate with morphological monocyte differentiation in AML subtypes. In contrast, there was an increased CAMP, CYP27B1, and CYP24A1 expression in AML4 and AML5 patients (Figures S1C-S1E), suggesting that, given that those genes are downstream positive targets of VDR signaling (Ma et al., 2012) , increased Vdr expression was associated with induction of VDR signaling. Therefore, undifferentiated and immature AML subtypes showed decreased Vdr expression compared with AML subtypes displaying monocytic differentiation.
VD is well known for its ability to induce myeloid progenitor differentiation into monocytes (Munker et al., 1986; Nagler et al., 1986) , and its activity relies on the expression of its receptor. To quantify Vdr expression in samples from healthy individuals and AML patients, we conducted an additional retrospective analysis (GEO: GSE9476) (Stirewalt et al., 2008) , confirming higher Vdr expression in AML4-5 subtypes compared with AML0-2 subtypes ( Figure 1B ). This analysis also revealed that Vdr expression in AML0-2 patients did not differ from that observed in CD34 + cells purified from bone marrow of healthy subjects or from peripheral blood in granulocyte colony-stimulating factor (G-CSF)-mobilized healthy donors ( Figure 1B) . Moreover, Vdr expression was similar between AML4-5 subtypes and bone marrow mononuclear cells (BMMCs) from healthy subjects ( Figure 1B ), but Vdr expression in AML4-5 subtypes was decreased in comparison with peripheral blood mononuclear cells (PBMCs) from healthy subjects ( Figure 1B ). Further investigation of Vdr expression during human normal hematopoiesis (http://servers.binf.ku.dk/hemaexplorer) confirmed that Vdr expression was low in hematopoietic progenitors and myeloid precursors and was increased in fully differentiated monocytes ( Figure S2A ). Therefore, Vdr expression in normal hematopoietic cells tracks with terminal monocyte differentiation.
To gain insight into the consequences of decreased Vdr expression in AML cells, we used hematopoietic precursors from Vdr-knockout mice (Vdr À/À ) (Van Cromphaut et al., 2001) transformed by retrovirus transduction of AML or myeloproliferative neoplasm (MPN)-associated oncogenes such as MLL-ENL or MLL-AF9 fusion genes or mutant FLT3 (internal tandem duplication [Flt3-ITD]). Monocyte differentiation was evaluated using flow cytometry with anti-CD11b and F4/80 (a widely used marker of murine macrophage population) antibodies and by cell morphology (May-Gr€ unwald Giemsa staining). In the absence of transduction, there was no difference between Vdr +/+ and Vdr À/À blood cell differentiation (data not shown). Transduction of Vdr À/À hematopoietic precursors resulted in a dramatic increase in undifferentiated CD11bÀ F4/80À double-negative cells ( Figure 1C ; Figure S2B ) and relatively less mature morphology ( Figure 1D ) compared with transduced wild-type (WT) cells, suggesting that Vdr inactivation is sufficient to limit myeloid differentiation in AML/MPN models.
To investigate the clinical relevance of Vdr expression in the pathogenesis of AML, we examined its relationship with patients' prognosis. Because Vdr expression was low in AML0-2 patients, we analyzed the outcome of variations in baseline Vdr expression only in AML4-5 patients from the GEO: GSE12417 series (n = 62 patients). OS was evaluated in patients with high (third tertile, n = 21 patients), intermediate (second tertile, n = 20 patients), and low (first tertile, n = 21 patients) Vdr expression. Log rank analysis of plotted curves showed that patients with higher Vdr expression had increased OS compared with those with lower Vdr expression ( Figure 1E ). Thus, Vdr expression could be used to refine patients' prognosis in AML4-5.
We also evaluated the impact of VDR signaling on AML relapse by analyzing the expression of VDR-target genes. For these experiments, we analyzed the expression level of cathelicidin antimicrobial peptide gene (CAMP) in a third cohort of well-defined patients treated with conventional chemotherapy regimens (all AML subtypes included except AML3; n = 90) (Castaigne et al., 2012) . Our results demonstrate that patients with elevated CAMP expression (a VDR-targeted gene) (n = 30,third tertile) exhibited an increased event-free survival (EFS) and relapse-free survival (RFS) compared with those with lower CAMP expression (n = 30, first tertile) ( Figures 1F and 1G ). Analysis of these AML patients also revealed increased Vdr expression in AML4-5 relative to AML0-2 subtypes ( Figure S3A ), further confirming observations from gene set databases GEO: GSE12417 and GEO: GSE9476. Moreover, in the GEO: GSE12417 cohort also, expression of CAMP and CYP27B1 correlated with survival (Figures S3B and S3C) . We also performed analysis on The Cancer Genome Atlas (TCGA) cohort (Ley et al., 2013) . Vdr expression was higher in AML4-5 subtypes ( Figure S3D ), and survival analysis performed on low and intermediate cytogenetics AML4-5 revealed an increased OS with high VDR ( Figure S3E ) or high CAMP (Figure S3F ) expression. Taken together, these data correlate Vdr/ VDR-target gene expression with improved prognosis in AML patients and with features of monocyte differentiation.
Vdr Inactivation Decreased Myeloid Precursor Numbers Undergoing Monocyte Differentiation and Increased HSC Engraftment
To gain further insight into the role of VDR in AML cells, we analyzed VDR involvement in hematopoiesis. Previous studies showed that Vdr À/À mice have normal numbers of circulating monocytes, suggesting that in steady state, VDR is not essential for myeloid differentiation (O'Kelly et al., 2002) . Complete blood cell counts from Vdr À/À and WT mice (both fed a standard diet) in steady-state conditions confirmed and extended these results, as no differences were observed in platelet, erythrocyte, granulocyte, and monocyte numbers between the two genotypes (Figure 2A and data not shown). In addition, there was no difference in cell numbers between Vdr À/À and WT animals in both bone marrow and spleen ( Figure 2B ). However, analysis of progenitor cells revealed that common myeloid progenitors (CMPs) and granulocyte-monocyte progenitors (GMPs) decreased in Vdr À/À mice compared with WT mice (Figures 2C and 2D) . In agreement, colony-forming cell (CFC) assays revealed that the ratio of macrophage (M) to granulocyte (G) colonies is decreased in Vdr À/À bone marrow ( Figure 2E ). Thus, the decreased number of monocyte progenitors in Vdr À/À mice suggests that VDR expression drives monocyte differentiation. , n = 10) and leukemic blasts from AML patients classified according to their FAB subtype (AML0-2, n = 8; AML4-5, n = 9). (C and D) Limited myeloid differentiation in Vdr À/À transformed cells. (C) Bone marrow hematopoietic precursors from Vdr À/À and WT mice (BALB/c background) were transduced with retrovirus coding for MLL-ENL, MLL-AF9, or Flt3-ITD. Cell differentiation was evaluated using flow cytometry with CD11b pan-myeloid and F4/80 monocyte markers. Results are presented as mean ± SEM (n R 3 mice per group). We then evaluated whether and how Vdr inactivation affects HSCs and hematopoietic progenitor cells (HPCs). Flow cytometry analyses of Vdr À/À mouse bone marrow cells revealed an increase in long-term HSCs (LT-HSCs) but not short-term HSCs (ST-HSC) in Vdr À/À mice ( Figure 2F ; Table S1 ). To investigate the role of VDR in HSC self-renewal potential, Vdr WT and Vdr À/À bone marrow cells were plated in methylcellulose and colonies were counted between days 7 and 10 of culture. Following serial replating, Vdr À/À cells maintained significant clonogenic potential in contrast to WT cells ( Figure 2G ). We then exposed Vdr WT and Vdr À/À mice to sublethal total body irradiation and monitored hematopoietic recovery. Vdr À/À mice showed a milder decrease of circulating mononuclear cells (MNC) and faster recovery ( Figure 2H ). To confirm these data, we performed competitive transplants. CD45.2 bone marrow cells from Vdr WT or Vdr À/À mice were infused to sublethally irradiated mice together with Vdr WT CD45.1 competitive bone marrow cells. Recipient mice showed an increased level of blood and bone marrow donor chimerism with Vdr À/À cells ( Figure 2I ). Subpopulation analysis showed decreased donor chimerism in CMP and GMP with Vdr À/À cells ( Figure 2J ). However, donor chimerism was increased in LT-HSC and ST-HSC when recipient mice were transplanted with Vdr À/À cells ( Figure 2K ). These data further support the role of Vdr in hematopoietic differentiation and in the homeostasis of HSC pool.
Prior literature suggests that low reactive oxygen species (ROS) levels increase HSC longevity, and high ROS levels promote myeloid differentiation (Callens et al., 2010a (Callens et al., , 2010b Jung et al., 2013; Tothova et al., 2007) . Because ROS control HSC homeostasis, we evaluated ROS levels in Lin À Sca-1 + c-Kit+ (LSK) cells by using the ROS indicator CM-H 2 DCFDA. Vdr À/À mice exhibited decreased numbers of LSK cells expressing high ROS levels compared with WT controls ( Figure S4 ). As steady-state HSC maintenance depends on their quiescent state , we searched for differences in cell cycle between WT and Vdr À/À progenitors. LSK cells from Vdr À/À mice had an increased percentage of quiescent G0 cells and a decreased percentage of cycling G1 and S-G2/M cells (Figures 2L and 2M) relative to WT controls. Altogether these results show that VDR increases ROS level and quiescence-to-cell-cycling transition in HSCs.
Vdr Invalidation in Oncogene-Transformed Cells Results in AML with Increased Leukemic Colony-Forming Ability
To further investigate the impact of Vdr expression in hematopoietic progenitors in a leukemic context, we first studied the expression of phenotypic markers in hematopoietic progenitors from WT and Vdr À/À mice transformed with Flt3-ITD, MLL-ENL, and MLL-AF9 fusion proteins. Using multiparametric flow cytometry analysis, an increased proportion of LSK cells was observed in Vdr À/À relative to WT transformed cells ( Figure 3A) .
Then, in order to examine the role of Vdr in LSC self-renewal potential, oncogene-transformed cells were plated in methylcellulose, and colonies were counted between days 7 and 10 of culture. The first round of plating revealed similar CFC numbers from WT and Vdr À/À transformed cells ( Figure 3B ). However, following serial replating (and as observed with non-transformed cells; see Figure 2G ), Vdr À/À transformed cells maintained significant clonogenic potential in contrast to WT cells ( Figure 3C ). Thus, Vdr À/À hematopoietic progenitors showed an enhanced clonogenic potential whether or not after oncogenic transformation. Furthermore, expression of LSK-related genes (EVI-1, HOXA-9, and MEIS-1), typically downregulated in committed myeloid progenitors (Chen et al., 2008) , was increased in Vdr À/À relative to WT transformed cells ( Figure 3D ) suggesting that inactivation of Vdr in oncogene-transformed cells results in a more immature phenotype, in line with our previous observations in healthy progenitor cells.
Figure 2. Vdr Inactivation Decreases Myeloid Precursors Engaged in Monocyte Differentiation and Increases Number of HSC
(A) In steady-state conditions, Vdr À/À mice present normal numbers of white blood cells (WBCs), monocytes, and granulocytes. WBC, granulocyte, and monocyte numbers in 8-to 16-week-old WT (n = 7) and Vdr À/À (n = 7) mice. (B) In steady-state conditions, Vdr-deficient mice present normal cellularity in bone marrow and spleen. Cellularity of the bone marrow of one femur and spleen cellularity of 24-week-old WT (n = 3) and Vdr À/À (n = 3) mice. (C) Representative fluorescence-activated cell sorting (FACS) staining profiles of the progenitor populations. CLP, common lymphoid progenitor; CMP, common myeloid progenitor; GMP, granulocyte/macrophage progenitor; LK, LinÀKit+; LSK, LinÀKit+Sca-1+; LRP, lineage-restricted progenitor; LT-HSC, long-term hematopoietic stem cell; MEP, megakaryocyte/erythroid progenitor; ST-HSC, short-term hematopoietic stem cell. (D) Decreased numbers of hematopoietic progenitors in Vdr À/À mice. Multiparametric flow cytometry quantification of hematopoietic progenitor cell populations in the bone marrow of WT and Vdr À/À 12-week-old mice (n = 6-8 mice per group). (E) Reduced numbers of monocyte progenitors in Vdr À/À mice. CFC assays of bone marrow cells from WT and Vdr À/À mice (n R 4 mice per group). (F) Increased numbers of LT-HSCs in Vdr À/À mice. Multiparametric flow cytometry quantification of hematopoietic precursors cells populations in bone marrow of 12-week-old WT and Vdr À/À mice (n = 6-8 mice per group). The proportion of a given population among total viable bone marrow cells is indicated. (G) Increased clonogenic potential of Vdr À/À cells. WT and Vdr À/À primary hematopoietic progenitors were plated (30,000 cells/condition) in semisolid methylcellulose media containing cytokines (M-3434) and scored following 7-10 days of culture. For replating assays, 30,000 cells were plated for each condition. Histograms represent numbers of colonies (n = 3; n R 6 mice per group). (H) Increased hematopoietic recovery in Vdr À/À mice. WT and Vdr À/À mice (n = 6 mice per group) were exposed to 4.5 Gy, and circulating mononuclear cells (MNCs) were monitored for 46 days. (I) Increased engraftment of Vdr À/À BM cells. Competitive transplantation assays were performed with 500,000 Vdr WT or Vdr À/À CD45.2 BM cells and 500,000 CD45.1 BM WT competitor cells (n = 3 mice per group). (J) Reduced numbers of monocyte progenitors with Vdr À/À BM cells in competitive transplantation assays. (K) Increased number of HSC with Vdr À/À BM cells in competitive transplantation assays. (L) Hematopoietic precursors from Vdr-deficient mice presented an increased quiescent status. Cell cycle analyses performed by Ki67 and PI labeling of bone marrow LSK cells from WT and Vdr À/À mice (n = 6 mice per group); left: representative histogram; right: mean ± SEM percentages of G0 cells are plotted. (M) Quantification of quiescent status. Results are presented as mean ± SEM; n R 3. ns, not significant; *p < 0.05, **p < 0.01, and ***p < 0.001. Finally, evaluation of the consequences of Vdr deletion in tumor initiation and progression was performed by crossing Vdr À/À mice with mice transformed with Flt3-ITD that develop myeloproliferative disease resembling chronic myelomonocytic leukemia (CMML). Competitive grafts were performed, and chimerism was analyzed according to the expression of Ly5.1 ( Figure 3E) . These cells present a higher capacity of engraftment during the first grafts, especially a better graft of pathological cells characterized by the expression of Mac1 and Gr1 ( Figure 3F ). Nevertheless, secondary grafts suggest that in this transformation model, lack of Vdr is not an initiating event of leukemogenesis, and these cells have a slightly increased capacity for grafting without over-representation of leukemic cells ( Figure 3G) .
Taken together, we demonstrate, using three different models of leukemic transformation, that Vdr À/À cells have an immature phenotype relative to WT cells associated with increased clonogenicity, suggesting that impaired Vdr expression favors an immature state of AML cells.
Promoter Methylation Decreases Vdr Expression in AML Cells, and Sensitivity to DNA Methyltransferase Inhibitors Is Dependent on Vdr Expression
To evaluate the molecular mechanisms of decreased Vdr expression in AML cells, we focused on the methylation profile of CpG islands (Akalin et al., 2012) in methylation-susceptible Vdr promoter region (Marik et al., 2010) . Analysis of the Vdr promoter from a previously published gene expression dataset (GEO: GSE18700) of 344 AML patients and 8 normal CD34+ cell samples revealed an important methylation of three clusters out of four that did not differ between AML and CD34 samples ( Figure 4A) . In vitro treatment with the DNA methyltransferase inhibitor 5-aza promoted a 2-fold increase in Vdr expression relative to vehicle in HL60 cells ( Figure 4B ). In addition, 5-aza, like the VDR agonists VD and inecalcitol (INEC), induced the expression of VDR-target genes CAMP and CYP24A1 in HL60 ( Figure 4C ) and primary AML cells ( Figure 4D ), suggesting that demethylating agents induce Vdr expression.
We then examined whether the anti-leukemic action of 5-aza on AML cells depends, at least in part, on its ability to induce Vdr expression and VDR-target genes. To explore this hypothesis, we studied the consequences of Vdr invalidation on AML cell sensitivity to 5-aza under pharmacological conditions (Fenaux et al., 2010) . MLL-ENL-, Flt3-ITD-, and MLL-AF9-transformed WT cells were sensitive to 5-aza in a dose-dependent manner, whereas MLL-ENL-, Flt3-ITD-, and MLL-AF9-transformed Vdr À/À cell survival was not altered by 5-aza treatment ( Figures  4E and 4F) . Taken together, these data indicate that in AML and normal cells, methylation of Vdr promoter controls Vdr expression, which in turn controls cell sensitivity to 5-aza.
Combined Demethylating Agents and VDR Agonists Synergistically Induced Cell Differentiation, Cell-Cycle Arrest, and Apoptosis in AML Cells, Resulting in Decreased Tumor Progression in Mice VDR agonists promote monocyte differentiation in AML cells (Amento et al., 1984; Nagler et al., 1986) . However, life-threatening hypercalcemia prevented the observation of clinical responses in clinical trials using VD (Kim et al., 2012) . INEC is a highly potent VDR agonist able to induce cell-cycle arrest in hematopoietic cells (Kim et al., 2012; Petrini et al., 1991) that has been developed to avoid hypercalcemia in patients with hematological malignancies, while maintaining proliferation inhibition of tumor cells (Kim et al., 2012; Petrini et al., 1991;  Figure 5A ). Doseresponse curves demonstrated that INEC was approximately 500 times more effective than VD in promoting AML cell differentiation ( Figure 5B ; Figure S5A ). Because Vdr expression was reduced in AML cells, we postulated that combination of 5-aza and INEC would increase Vdr expression by decreasing promoter methylation and activate VDR, respectively. Whereas 5-aza, VD, or INEC alone promoted a modest increase in myeloid differentiation, their combined use led to a significant increase in differentiation as determined by CD14 and CD11b expression in normal CD34+ cells, primary AML cells and AML cell lines, and HL60 cells ( Figure 5C; Figures S5B, S5C, and S7A ). Further morphological analysis confirmed these observations in HL60 cells ( Figure S5D ). This synergistic effect on differentiation was also observed in the mRNA expression of monocyte differentiation markers (TREML2, SERPINB8), which were upregulated in cells treated with VD agonists and demethylating agent (Figure 5D ; Figure S5F ). Moreover, in HL60 cells, granulocyte marker expression (NE, PRTN3) was downregulated in comparison with controls, suggesting that this drug association favors monocyte differentiation over granulocyte differentiation ( Figure 5D ), as previously shown for VD (Callens et al., 2010a) . As expected, the synergistic effect between VDR agonists and DNA methyltransferase inhibitors was not restricted to 5-aza, as DAC showed a similar ability in promoting AML cell differentiation ( Figure S6 ). (A) Increased frequency of LSK cells in Vdr À/À transformed cells. Left: representative dot plots of Lin À Sca-1 + KIT + (LSK) cells from WT and Vdr À/À bone marrow cells following leukemic transformation with MLL-AF9 oncogene. Right: quantification of LSK + cells in WT and Vdr À/À cells transduced with retrovirus coding for MLL-ENL, MLL-AF9, or Flt3-ITD (n R 3 mice per group). (B and C) Increased clonogenic potential of Vdr À/À transformed cells. Oncogene-transformed WT and Vdr À/À primary hematopoietic progenitors were plated (30,000 cells/condition) in semisolid methylcellulose media containing cytokines and scored following 7-10 days of culture (B). For replating assays (C), 30,000 cells were plated for each condition. Histograms represent numbers of colonies (n = 3; six mice per group). (D) Increased expression of stemness-related genes in Vdr À/À transformed cells. WT and Vdr À/À Flt3-ITD-transformed cells were analyzed for expression of EVI-1, HOXA-5, HOXA-9, and MEIS-1 using qPCR analysis (n R 3 mice). (E) Experimental protocol used to investigate the competitive repopulating ability of Vdr +/+ or Vdr À/À 3 Flt3-ITD cells. (F) Increased peripheral blood engraftment in first transplantation assays with Vdr À/À 3 Flt3-ITD cells. (G) Increased bone marrow engraftment in second transplantation assays with Vdr À/À 3 Flt3-ITD cells. All results are presented as mean ± SEM; n R 3. ns, not significant; *p < 0.05, **p < 0.01, and ***p < 0.001. Combined 5-aza/INEC association was also effective in inducing cell-cycle arrest ( Figure 5E ) and upregulation of cyclin-dependent kinase (cdk) inhibitors including p15, p21, and p27 ( Figure 5F; Figures S7A and S7B) . But there was no additive or synergistic effect in inducing apoptosis ( Figure S7C ) of leukemic cell lines as evidenced by annexin V-positive and TO-PRO-3 negative staining, further suggesting that the association provides significant anti-leukemic effects. Mice passively transferred with Flt3-ITD/Npm1c AML blasts (Mupo et al., 2013) and treated in vivo with INEC and DAC presented increased survival compared with vehicle-treated or DAC-treated animals (Figure S7D) . In another in vivo tumor xenograft model with U937 cell line, 5-aza/INEC therapy resulted in an increased survival compared with control.
MLL-ENL
In this in vivo model ( Figure 5G ), we did not observe a significant effect on survival or tumor growth of single treatments with 5-aza or INEC ( Figure 5H) , indicating a combined effect of this regimen. Altogether, these results indicate that when used in combination, VDR agonists and demethylating agents act to activate VDR signaling resulting in impaired growth, increased differentiation, and apoptosis of AML cells in vitro and in vivo.
Targeting VDR Signaling Impairs Colony-Forming Ability and LSC Pool in AML Models
LSCs are a relatively more quiescent subset of leukemic cells. However, they can be followed functionally by their ability to maintain clonogenicity in serial replating assays and to sustain leukemia initiation and resistance to chemotherapy, and therefore they are believed to be responsible for relapses. Because of the hematological characteristics observed in Vdr À/À mice, we hypothesized that VDR agonists could efficiently target LSCs. First, to test this hypothesis in vitro, we performed serial replating experiments with bone marrow precursors from WT mice transduced with the Flt3-ITD construct in semisolid media containing INEC or vehicle ( Figure 6A ). Flt3-ITD-transformed cells in INEC containing cultures exhibited a 2-fold decrease in clonogenic potential compared with vehicle-treated cells upon first replating (Figure 6A) . Subsequent replating revealed that INEC treatment induced a progressive loss of LSCs with virtually no colony growth at the fourth round of plating relative to vehicle-treated cells (Figure 6A) . To examine if the INEC effect was reversible, INEC-treated cultures were divided at the second plating stage into two groups treated either with INEC or vehicle for the subsequent rounds of replating ( Figure 6A) . INEC wash-out reestablished CFC numbers to levels observed in cells originally treated with vehicle or induced a rebound to higher levels, suggesting that continuous treatment with VDR agonists was required to maintain the selective pressure on colony forming cells ( Figure 6A ). Of note, when the same experiments were performed with Flt3-ITD-transformed Vdr À/À cells, no effect of INEC was observed, demonstrating that its effect relied on VDR (data not shown). Taken together, in vitro colony replating assays suggest that (1) Vdr is implicated in the control of LSC homeostasis and (2) VDR agonists have the potential to decrease their colony forming capacity.
We then tested the ability of VDR agonists to target LSC in vivo. Flt3-ITD/Npm1c AML bone marrow cells (Mupo et al., 2013) treated in vitro with or without INEC for 6 days increased expression of myeloid differentiation markers compared with vehicletreated cells ( Figure 6B ). Mice adoptively transferred with these INEC-treated cells did not develop aggressive leukemia ( Figure 6C ). Immunophenotypic analysis of their blood cells did not reveal the presence of leukemic cells, and their hemoglobin levels and platelet numbers remained normal ( Figure 6D ). This dramatically contrasted with mice transplanted with vehicletreated cells, which developed aggressive leukemia burden, as evidenced by increased leukocyte numbers, anemia, and thrombocytopenia (Mupo et al., 2013;  Figure 6D ). Mice that underwent adoptive transfer of vehicle-treated cells also demonstrated decreased numbers of CD11b+Ly6G+ myeloid cells in both bone marrow and spleen ( Figure 6D ) and splenomegaly (Figure 6E) , features that were absent in mice that underwent adoptive transfer using INEC-treated cells. Finally, mice transplanted with INEC-treated cells demonstrated a dramatic reduction in mortality ( Figure 6F ). To further provide evidence that VDR targeting decreases LSCs, we performed secondary transplantation using leukemic mice treated with the drugs in vivo (vehicle, INEC, DAC, and DAC-INEC) and monitored disease progression in the secondary recipient mice. In this setting, only DAC-INEC and INEC-treated mice had significantly increased survival ( Figure 6G ), without a difference between both treatments. Therefore, in a Flt3-ITD/Npm1c model, VDR agonists control LSC homeostasis in vitro and in vivo. They promoted growth Results are presented as mean ± SEM; n R 3. ns, not significant; *p < 0.05, **p < 0.01, and ***p < 0.001. arrest of clonogenic progenitors and their increased differentiation in vitro, resulting in reduced leukemogenesis and increased survival in vivo.
DISCUSSION
AML leukemogenesis has been described as a multistep process with driver and passenger mutations. Those mutations can result in a differentiation arrest, deregulation of cell signaling, and uncontrolled cell proliferation (Welch et al., 2012) . VD signaling induces differentiation and cell growth arrest. Therefore, targeting VDR might be an interesting therapeutic alternative in AML. However, life-threatening side effects of VD limit its use in AML patients.
Here we show that high expression of Vdr and VDR-targeted gene (CAMP) is associated with an increase of overall patient survival. In a study of 5,848 AML patients, AML0 subtype was associated with decreased RFS and OS, suggesting that an immature phenotype could result in a worsened disease outcome (Walter et al., 2013) . Our studies in AML patients suggest that low Vdr expression could contribute to this poorer prognosis by preventing AML cell differentiation and/or, more likely, by preventing LSC exhaustion. In line with the latter hypothesis, among more differentiated AML4/5 subtypes, low Vdr expression was also associated with a poorer prognosis. We conclude that VDR is a new genetic modifier significantly contributing to the expression of different AML subtypes with a potential impact on disease prognosis and outcome.
Previous studies did not reveal differences in peripheral blood monocyte numbers in WT and Vdr À/À mice, suggesting that Vdr expression is not essential for monocyte differentiation (O'Kelly et al., 2002) . Our results confirmed that in steady-state conditions monocyte numbers are not altered in Vdr À/À mice. In contrast to mature cells, Vdr inactivation appeared to be essential for the control of HSC and myeloid progenitor differentiation. Indeed, HSCs from Vdr À/À mice showed an increased quiescence status and a reduced ability to accumulate ROS, two characteristics that have been implicated in the protection of HSCs pool from premature exhaustion, thereby allowing its long-term maintenance (Amrani et al., 2011; Takubo et al., 2013; Tothova et al., 2007) .
Despite the use of intensive chemotherapy and allogeneic BMT, relapsed AML remains a disease associated with a poor prognosis. Relapses are associated with the presence of LSCs characterized by their longevity and resistance to chemotherapy. In APL, it has been shown that targeting RAR results in LSC exhaustion (Ablain et al., 2013) . Here we demonstrate that ablation of Vdr leads to an increased number of functional HSCs. In a Flt3-ITD/ Npm1c murine model of AML, the use of VDR agonists reduced engraftment of AML in serial transplantation assay, suggesting that VDR targeting could impair LSC activity and prevent relapse. Furthermore, oncogene-transformed Vdr À/À cells exhibited impaired differentiation and increased self-renewal potential, indicating that VDR activation targets major pathways controlling both cell differentiation and LSC homeostasis. Likewise, VDR agonists promoted AML cell differentiation. Taken together, our data suggest that activating VDR signaling in AML cells prevents relapse by decreasing LSC number and therefore VDR agonists seem a promising therapeutic intervention.
Methylation is a frequent process occurring in mammalian genome, and genome-wide demethylation is essential for embryo development (Feng et al., 2010) . In hematopoiesis epigenetic modifications also occur, and, for example, 5 0 -CpG-3 0 dinucleotide demethylation is essential for erythropoiesis (Shearstone et al., 2011) . In hematological malignancies a set of genes is silenced by epigenetic modifications, resulting in myeloid differentiation arrest, a feature of AML. However, the molecular mechanisms resulting in the specificity of gene promoters that are methylated remains poorly understood. Our data demonstrate that Vdr promoter is methylated in both AML and CD34 + cells. In agreement, we also show that DNA methyltransferase inhibitors (e.g., 5-aza or DAC) can induce Vdr/VDRtarget gene expression. In agreement, in vivo treatment of mice with a combination of 5-aza and INEC prolonged their survival, although DAC seemed without effect, probably because of reduced stability or non-optimal dosage of DAC in the mouse. These genes may participate not only in cell differentiation block but also in the prevention of AML progression, mainly by reducing the pool of LSCs. Therefore, regulation of Vdr expression by epigenetic modification uncovers a new role for this nuclear receptor in AML and explains, at least in part, the effect of hypomethylating agents in this disease. Results are presented as mean ± SEM; n R 3. ns, not significant; *p < 0.05, **p < 0.01, and ***p < 0.001.
Our in vitro data demonstrate that there is a potentiation effect between the VD analog INEC and hypomethylating agents to induce differentiation, cell growth arrest, and apoptosis of various AML cell lines and primary AML cells. In agreement, our in vivo observations using both U937 xenograft model and Flt3-ITD/Npm1c model show that association of VDR agonists with hypomethylating agents decreased tumor burden better than either compound alone. However, in our experimental conditions, this combination did not significantly improve survival on secondary transplantation over VD analog alone, suggesting that the latter was sufficient to decrease LSC activity. Therefore, VD analogs alone might be enough to affect LSCs but not to control AML blast proliferation. VDR agonists seem a promising therapeutic intervention. Targeting CSLs could theoretically lead to cytopenia because of the exhaustion of HSCs. However, this phenomenon has not been observed in APL treated with ATRA and ATO, suggesting that such association remains a clinical option (Testa and Lo-Coco, 2015) . VD administration did not achieve HSC exhaustion. To our knowledge, there are no consistent data in the literature to support that VD alone is able to achieve HSC exhaustion in patients despite a large number of AML patients treated with vitamin D. A refined combination of VD analogs and hypomethylating agents might be interesting to control tumor bulk and to prevent relapse. A clinical trial is ongoing addressing this question (NCT02802267).
In summary, we identified a novel role for Vdr and VDR signaling in normal and malignant hematopoiesis. The increases in hematopoietic precursor number and myeloid progenitor populations in Vdr À/À mice suggest that Vdr expression is critical for normal HSC homeostasis. In hematopoietic malignancies, Vdrtargeted gene expression correlates with improved prognosis in AML patients, whereas Vdr inactivation in AML cells results in limited myeloid differentiation and increased clonogenic potential of LSCs. In both AML and CD34 + cells, Vdr expression might be inactivated by promoter methylation. Conversely, reversal of Vdr promoter methylation in leukemia cells results in myeloid differentiation, decrease of LSC number, and reestablishment of responsiveness to VD. Taken together, our data suggest that Vdr inactivation results in both limited myeloid differentiation and maintenance of HSC and LSC pools, while induction of VDR signaling decreases LSC numbers, suggesting that it might be relevant in preventing relapses. This latter effect may represent a new paradigm potentially applicable to other malignant diseases.
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EXPERIMENTAL MODELS AND SUBJECT DETAILS
Clinical samples
All human studies were approved by the institutional review boards of participating institutions. Peripheral bloods cells from AML patients were obtained after written informed consent. Peripheral blood was collected at the initial diagnosis before the administration of any treatment. Mononuclear cells were purified by Ficoll-hypaque (PAA laboratories) density centrifugation and resuspended in DMEM (Invitrogen) supplemented with 15% Fetal Calf Serum (FCS) (Biowest), 100 ng/ml stem cell factor (SCF), 10 ng/ml IL-3 and 25ng/ml FLT3-L (Peprotech).
Cell lines AML cell lines (Promyeloblastic (HL60), myelocytic (OCI-AML3), monoblastic (THP1 and U937)) were cultured in RPMI-1640 medium (Invitrogen) supplemented with 10% FCS and antibiotics.
Mice
Vdr À/À mice and control Vdr +/+ littermates (Van Cromphaut et al., 2001) were fed ad libitum with a standard rodent diet. All animal experiments were approved by the ''Institutional Animal Care and Use Committee'' at Inserm.
Flt3-ITD/ Npm1c mouse model For Flt3-ITD/ Npm1c model, C57BL6 recipient mice (irradiated with 9 Gy) were injected with 10 5 bone marrow cells from Flt3-ITD/ Npm1c mice (Mupo et al., 2013) cultured with 10 ng/ml IL-3, 50 ng/ml SCF and 10ng/ml IL-6 (Peprotech) in Stempro medium in the presence or absence of Inecalcitol (10nM). In some cases injected mice were treated with INEC (20 mg per mouse via intraperitoneal injection, five days weekly) or DAC (0.5mg/kg via intraperitoneal injection 5 times weekly). The dose of DAC was adapted from the dose used for the treatment of patients.
Tumor xenografts
To establish tumors, 10-week old female athymic Nude mice (Janvier laboratories, France) were injected subcutaneously with 5 3 10 6 U937 mixed with Matrigel (BD Biosciences) (1:1, vol:vol). The mice also received intraperitoneal injections of 5-Azacytidine (Celgene) (5 mg/kg on day 5, 7, 9, 11 and 13), Inecalcitol (Hybrigenics) (20 mg/day 3 times a week), combination of 5-Azacytidine and Inecalcitol or PBS as a vehicle control. Tumor growth was measured as previously described (Lepelletier et al., 2007) .
Human samples microarray analysis AML and HSPC samples were described previously (Metzeler et al., 2008) and are available at the GEO database. Analysis was performed using R 2.14.0. Raw data were generated using the RMA package. For comparison of different array sets, raw expression data were normalized to the mean of control GAPDH probe sets. For methylation analysis, AML and HSPC samples were described previously (Figueroa et al., 2010) ; (Metzeler et al., 2008) and are available at the GEO database. The microarray design is documented in accession number GPL6604. Data from this study are publicly available by accessing Gene Expression Omnibus accession number GSE18700. Data were processed using standard pipeline. 
